New lab licenses strengthen nationwide access to CNS oncology diagnostics

Plus Therapeutics (NASDAQ: PSTV) has announced a major regulatory and commercialization milestone with the expansion of laboratory licenses for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) test.

The company has now been granted lab licenses to provide the CNSide® TCE laboratory developed test (LDT) in California, Rhode Island, and Maryland, bringing CNSide Diagnostics’ total licensed footprint to 48 U.S. states, representing coverage of over 90% of the U.S. population.

Expanding Nationwide Access to Advanced CNS Cancer Diagnostics

This regulatory milestone significantly expands access to CNSide’s advanced molecular diagnostic platform for physicians treating patients with cancers affecting the central nervous system, including leptomeningeal metastases and other complex neuro-oncology conditions.

The CNSide® TCE test is designed to deliver quantitative, clinically actionable insights from cerebrospinal fluid, enabling earlier detection, improved disease monitoring, and more informed treatment decisions.

Accelerating CNSide’s Commercialization Momentum

With licenses now active in 48 states, CNSide Diagnostics is positioned for broad clinical adoption across the United States. This expansion strengthens Plus Therapeutics’ ability to support healthcare providers nationwide and reflects the company’s continued progress toward scalable commercialization of its CNS oncology diagnostic solutions.

Full announcement: https://lnkd.in/gYEnQHXT

Explore CNSide: https://cnside-dx.com

About CNSide Diagnostics

CNSide Diagnostics is a molecular diagnostics company focused on advancing precision diagnostics for cancers of the central nervous system, empowering clinicians with clearer insights and improved patient outcomes.

#PlusTherapeutics #PSTV #CNSide #CNSideDiagnostics #PrecisionDiagnostics #NeuroOncology #CancerDiagnostics #ClinicalInnovation #LaboratoryMedicine #MolecularDiagnostics #LeptomeningealMetastases #HealthcareInnovation